Recent advances of novel targeted therapy for squamous cell carcinoma of the head and neck

  • Jed A. Katzel | zli@aptiumoncology.com Department of Hematology and Oncology, Saint Vincent’s Hospital, Manhattan; New York Medical College, Valhalla; Saint Vincent’s Comprehensive Cancer Center, New York, United States.
  • Michael P. Fanucchi Department of Hematology and Oncology, Saint Vincent’s Hospital, Manhattan; New York Medical College, Valhalla; Saint Vincent’s Comprehensive Cancer Center, New York, United States.
  • William A. Cook Department of Hematology and Oncology, Saint Vincent’s Hospital, Manhattan; New York Medical College, Valhalla; Saint Vincent’s Comprehensive Cancer Center, New York, United States.
  • Zujun Li Department of Hematology and Oncology, Saint Vincent’s Hospital, Manhattan; New York Medical College, Valhalla; Saint Vincent’s Comprehensive Cancer Center, New York, United States.

Abstract

Targeted therapies have proven beneficial for patients suffering from a number of different malignancies, including cancers of the head and neck. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor has shown benefit in combination with radiation for untreated patients or as a single agent for patients with platinum resistant disease. Cetuximab is the only targeted agent currently approved by the Federal Drug Administration for the treatment of head and neck cancer. A number of other agents have shown promising initial results including intracellular tyrosine kinase inhibitors, agents targeting vascular endothelial growth factor receptor, as well as other classes of novel therapies. Some of the data supporting the use of targeted therapy, including agents not yet approved in head and neck cancer, will be presented in this review. As our understanding of the cancer cell signaling pathways and novel targeted agents increases, the potential for treatment with reduced toxicity and improved clinical outcomes will become a reality.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.
Published
2011-12-14
Info
Issue
Section
Reviews
Keywords:
Epidermal growth factor receptor - Cetuximab - Vascular endothelial growth factor receptor - Head and neck cancer - Targeted therapy
Statistics
  • Abstract views: 1208

  • FULL TEXT: 178
How to Cite
Katzel, J. A., Fanucchi, M. P., Cook, W. A., & Li, Z. (2011). Recent advances of novel targeted therapy for squamous cell carcinoma of the head and neck. Oncology Reviews, 3(3), 149-160. https://doi.org/10.4081/oncol.2009.89